India’s vaccine think-tank the National Technical Advisory Group on Immunisation (NTAGI) meeting to discuss vaccination protocol for 5-12 year old kids remained inconclusive on Wednesday, according to sources.
The NTAGI members reviewed data from vaccine makers for 5-12 year old kids, but no decision on whether to expand the program to this younger group was taken.
Last month the regulator had approved two vaccines--Serum Institute's Covovax and Biological E-made Corbevax--for use in 5-12-year-old children.
However the NTAGI decides on whether these would be used in India's Covid-19 vaccination programme.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.